Research programme: cancer vaccines - ODC Therapy

Drug Profile

Research programme: cancer vaccines - ODC Therapy

Alternative Names: ODC-0601; ODC-0801; ODC-0802; ODC-0901

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ODC Therapy
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-cancer in USA (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top